Top

Published in:

09-07-2022 | Chronic Pancreatitis | Review Article

KRAS Mutations in Peripheral Blood (with or without CA19-9) for Differential Diagnosis of Pancreatic Cancer and Chronic Pancreatitis: a Systematic Review and Meta-analysis

Authors: Weiwei Li, Jianli Wang, Yanhua Li, Qiuju Yue, Miaohang Cui, Jinlong Liu

Published in: Indian Journal of Surgery | Issue 4/2022

Abstract

Differentiation between pancreatic cancer and chronic pancreatitis remains a challenge. This meta-analysis aims to explore the diagnostic value of KRAS mutations in peripheral blood [with or without carbohydrate antigen 19–9 (CA19-9)] in pancreatic cancer and chronic pancreatitis and to discern the best method for the diagnosis of pancreatic cancer.

We conducted a comprehensive search of articles indexed in the PubMed, Embase, and Web of Science databases. We not only discerned overall KRAS mutations in peripheral blood, but also evaluated and compared the diagnostic value of both KRAS mutations and CA19-9 levels.

A total of 13 studies were included in this meta-analysis. The pooled sensitivity and specificity of overall KRAS mutations in peripheral blood were 46% [95% confidence interval (CI): 29–63%] and 92% (95% CI: 86–96%), respectively. Then, we analyzed the diagnostic value of different combinations of KRAS mutations and CA19-9; ultimately, the series combinative detection of KRAS mutations and CA19-9 showed the highest diagnostic specificity, up to 98% (95% CI: 88–100%). In paralleled combinative detection of KRAS mutations and CA19-9, the diagnostic performance was significantly improved, with a sensitivity of 93% (95% CI: 84–97%) and specificity of 75% (95% CI: 53–89%).

KRAS mutations in peripheral blood have a high diagnostic value in the differential diagnosis of pancreatic cancer and chronic pancreatitis. Different combinations of CA19-9 and KRAS mutations may have variable roles in the diagnosis or screening of pancreatic cancer and have substantial potential as a tumor marker in the diagnosis of pancreatic cancer.

Khalaf N, El-Serag HB, Abrams HR, Thrift AP (2021) Burden of pancreatic cancer: from epidemiology to practice. Clin Gastroenterol Hepatol : Off Clin Pract J Am Gastroenterol Assoc 19(5):876–84. https://doi.org/10.1016/j.cgh.2020.02.054CrossRef

Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA: Cancer J Clin 70(1):7–30. https://doi.org/10.3322/caac.21590CrossRef

Ryan DP, Hong TS, Bardeesy N (2014) Pancreatic adenocarcinoma. New Engl J Med. 371(11):1039–49. https://doi.org/10.1056/NEJMra1404198CrossRefPubMed

Poruk KE, Gay DZ, Brown K, Mulvihill JD, Boucher KM, Scaife CL et al (2013) The clinical utility of CA 19–9 in pancreatic adenocarcinoma: diagnostic and prognostic updates. Curr Mol Med. 13(3):340–51. https://doi.org/10.2174/1566524011313030003CrossRefPubMedPubMedCentral

Kitano M, Yoshida T, Itonaga M, Tamura T, Hatamaru K, Yamashita Y (2019) Impact of endoscopic ultrasonography on diagnosis of pancreatic cancer. J Gastroenterol. 54(1):19–32. https://doi.org/10.1007/s00535-018-1519-2CrossRefPubMed

Capurso G, Signoretti M, Valente R, Arnelo U, Lohr M, Poley JW et al (2015) Methods and outcomes of screening for pancreatic adenocarcinoma in high-risk individuals. World J Gastrointest Endosc. 7(9):833–42. https://doi.org/10.4253/wjge.v7.i9.833CrossRefPubMedPubMedCentral

Buscail L, Bournet B, Cordelier P (2020) Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer. Nat Rev Gastroenterol Hepatol 17(3):153–68. https://doi.org/10.1038/s41575-019-0245-4CrossRefPubMed

Osumi H, Shinozaki E, Yamaguchi K, Zembutsu H (2019) Clinical utility of circulating tumor DNA for colorectal cancer. Cancer Sci. 110(4):1148–55. https://doi.org/10.1111/cas.13972CrossRefPubMedPubMedCentral

Ignatiadis M, Lee M, Jeffrey SS (2015) Circulating tumor cells and circulating tumor DNA: challenges and opportunities on the path to clinical utility. Clin Cancer Res: Off J Am Assoc Cancer Res 21(21):4786–800. https://doi.org/10.1158/1078-0432.Ccr-14-1190CrossRef

10.

Marchese R, Muleti A, Pasqualetti P, Bucci B, Stigliano A, Brunetti E et al (2006) Low correspondence between K-ras mutations in pancreatic cancer tissue and detection of K-ras mutations in circulating DNA. Pancreas. 32(2):171–7. https://doi.org/10.1097/01.mpa.0000202938.63084.e3CrossRefPubMed

11.

Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB et al (2011) QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155(8):529–36. https://doi.org/10.7326/0003-4819-155-8-201110180-00009CrossRefPubMed

12.

Jackson D, White IR, Riley RD (2012) Quantifying the impact of between-study heterogeneity in multivariate meta-analyses. Stat Med. 31(29):3805–20. https://doi.org/10.1002/sim.5453CrossRefPubMedPubMedCentral

13.

Adamo P, Cowley CM, Neal CP, Mistry V, Page K, Dennison AR et al (2017) Profiling tumour heterogeneity through circulating tumour DNA in patients with pancreatic cancer. Oncotarget. 8(50):87221–33. https://doi.org/10.18632/oncotarget.20250CrossRefPubMedPubMedCentral

14.

Castells A, Puig P, Móra J, Boadas J, Boix L, Urgell E et al (1999) K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance. J Clin Oncol: Off J Am Soc Clin Oncol 17(2):578–84. https://doi.org/10.1200/jco.1999.17.2.578CrossRef

15.

Däbritz J, Preston R, Hänfler J, Oettle H (2009) Follow-up study of K-ras mutations in the plasma of patients with pancreatic cancer: correlation with clinical features and carbohydrate antigen 19–9. Pancreas. 38(5):534–41. https://doi.org/10.1097/MPA.0b013e31819f6376CrossRefPubMed

16.

Dai MH, Zhao YP, Cai LX, Zhu Y (2003) Combined detection of K-ras mutation and CA 19–9 level in plasma of patients with pancreatic cancer. Zhonghua Wai Ke Za Zhi [Chin J Surg] 41(5):332–335

17.

Dianxu F, Shengdao Z, Tianquan H, Yu J, Ruoqing L, Zurong Y et al (2002) A prospective study of detection of pancreatic carcinoma by combined plasma K-ras mutations and serum CA19–9 analysis. Pancreas. 25(4):336–41. https://doi.org/10.1097/00006676-200211000-00003CrossRefPubMed

18.

Kinugasa H, Nouso K, Miyahara K, Morimoto Y, Dohi C, Tsutsumi K et al (2015) Detection of K-ras gene mutation by liquid biopsy in patients with pancreatic cancer. Cancer. 121(13):2271–80. https://doi.org/10.1002/cncr.29364CrossRefPubMed

19.

Le Calvez-Kelm F, Foll M, Wozniak MB, Delhomme TM, Durand G, Chopard P et al (2016) KRAS mutations in blood circulating cell-free DNA: a pancreatic cancer case-control. Oncotarget. 7(48):78827–40. https://doi.org/10.18632/oncotarget.12386CrossRefPubMedPubMedCentral

20.

Maire F, Micard S, Hammel P, Voitot H, Lévy P, Cugnenc PH et al (2002) Differential diagnosis between chronic pancreatitis and pancreatic cancer: value of the detection of KRAS2 mutations in circulating DNA. Br J Cancer. 87(5):551–4. https://doi.org/10.1038/sj.bjc.6600475CrossRefPubMedPubMedCentral

21.

Mulcahy HE, Lyautey J, Lederrey C, QiChen X, Anker P, Alstead EM et al (1998) A prospective study of K-ras mutations in the plasma of pancreatic cancer patients. Clin Cancer Res: an off J Am Assoc Cancer Res 4(2):271–5

22.

Theodor L, Melzer E, Sologov M, Idelman G, Friedman E, Bar-Meir S (1999) Detection of pancreatic carcinoma: diagnostic value of K-ras mutations in circulating DNA from serum. Dig Dis Sci 44(10):2014–9. https://doi.org/10.1023/a:1026618317716CrossRefPubMed

23.

Yamada T, Nakamori S, Ohzato H, Oshima S, Aoki T, Higaki N et al (1998) Detection of K-ras gene mutations in plasma DNA of patients with pancreatic adenocarcinoma: correlation with clinicopathological features. Clin Cancer Res: off J Am Assoc Cancer Res 4(6):1527–1532

24.

Zhang Y, Ji SR, Feng DX, Ji J, Han TQ (2003) Significance of detection of K-ras gene mutations and CA19–9 in serum for diagnosis of pancreatic carcinoma. Ai zheng = Aizheng = Chin J Cancer 22(3):295–7

25.

Zhang L, Sanagapalli S, Stoita A (2018) Challenges in diagnosis of pancreatic cancer. World J Gastroenterol 24(19):2047–60. https://doi.org/10.3748/wjg.v24.i19.2047CrossRefPubMedPubMedCentral

26.

Yang J, Li J, Zhu R, Zhang H, Zheng Y, Dai W et al (2014) K-ras mutational status in cytohistological tissue as a molecular marker for the diagnosis of pancreatic cancer: a systematic review and meta-analysis. Dis Markers. 2014:573783. https://doi.org/10.1155/2014/573783CrossRefPubMedPubMedCentral

27.

Yang J, Li S, Li J, Wang F, Chen K, Zheng Y et al (2016) A meta-analysis of the diagnostic value of detecting K-ras mutation in pancreatic juice as a molecular marker for pancreatic cancer. Pancreatol: Off J Int Assoc Pancreatol (IAP) [et al] 16(4):605–14. https://doi.org/10.1016/j.pan.2016.04.033CrossRef

28.

Goonetilleke KS, Siriwardena AK (2007) Systematic review of carbohydrate antigen (CA 19–9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol : J Eur Soc Surg Oncol Br Assoc Surg Oncol 33(3):266–70. https://doi.org/10.1016/j.ejso.2006.10.004CrossRef

29.

Fahrmann JF, Schmidt CM, Mao X, Irajizad E, Loftus M, Zhang J et al (2021) Lead-time trajectory of CA19–9 as an anchor marker for pancreatic cancer early detection. Gastroenterology 160(4):1373–83.e6. https://doi.org/10.1053/j.gastro.2020.11.052CrossRefPubMed

30.

Su SB, Qin SY, Chen W, Luo W, Jiang HX (2015) Carbohydrate antigen 19–9 for differential diagnosis of pancreatic carcinoma and chronic pancreatitis. World J Gastroenterol. 21(14):4323–33. https://doi.org/10.3748/wjg.v21.i14.4323CrossRefPubMedPubMedCentral

31.

Buscail E, Maulat C, Muscari F, Chiche L, Cordelier P, Dabernat S et al (2019) Liquid biopsy approach for pancreatic ductal adenocarcinoma. Cancers 11(6):852. https://doi.org/10.3390/cancers11060852CrossRefPubMedCentral

32.

Huerta M, Roselló S, Sabater L, Ferrer A, Tarazona N, Roda D et al (2021) Circulating tumor DNA detection by digital-droplet PCR in pancreatic ductal adenocarcinoma: a systematic review. Cancers 13(5):994. https://doi.org/10.3390/cancers13050994CrossRefPubMedPubMedCentral

Title: KRAS Mutations in Peripheral Blood (with or without CA19-9) for Differential Diagnosis of Pancreatic Cancer and Chronic Pancreatitis: a Systematic Review and Meta-analysis
Authors: Weiwei Li
Jianli Wang
Yanhua Li
Qiuju Yue
Miaohang Cui
Jinlong Liu
Publication date: 09-07-2022
Publisher: Springer India
Keywords: Chronic Pancreatitis
Pancreatic Cancer
Pancreatic Cancer
Published in: Indian Journal of Surgery / Issue 4/2022
Print ISSN: 0972-2068
Electronic ISSN: 0973-9793
DOI: https://doi.org/10.1007/s12262-022-03475-4

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

KRAS Mutations in Peripheral Blood (with or without CA19-9) for Differential Diagnosis of Pancreatic Cancer and Chronic Pancreatitis: a Systematic Review and Meta-analysis

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2022

Does CA 125 Predict Peritoneal Dissemination in Patients with Gastric Cancer?

Laparoscopic Ventral Mesh Rectopexy with Resection of Dolichocolon for Treatment of Obstructed Defecation Syndrome: Technical Report

One Man—Six Spleens

Awake Video-Assisted Thoracoscopic Surgery with Erector Spinae Plane Block

Blue Rubber Bleb Nevus Syndrome

Prospective Comparative Study of Laparoscopic Totally Extra-Peritoneal Repair for Inguinal Hernia with Light Weight Polypropylene Mesh V/S 3D Anatomically Shaped Large Pore Polypropylene Mesh